Verici Dx plc (LON:VRCI – Get Free Report)’s share price was down 0.3% during trading on Monday . The stock traded as low as GBX 7.50 ($0.09) and last traded at GBX 7.73 ($0.10). Approximately 142,961 shares were traded during trading, a decline of 60% from the average daily volume of 359,174 shares. The stock had previously closed at GBX 7.75 ($0.10).
Verici Dx Price Performance
The company has a debt-to-equity ratio of 9.28, a quick ratio of 8.49 and a current ratio of 2.58. The firm has a market cap of £18.80 million, a P/E ratio of -155.00 and a beta of 1.48. The company has a 50-day moving average of GBX 9.30 and a 200 day moving average of GBX 8.85.
Verici Dx Company Profile
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its lead products comprise Tutivia, a post-transplant test focused on acute rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
Recommended Stories
- Five stocks we like better than Verici Dx
- Most Volatile Stocks, What Investors Need to Know
- High-Yield Texas Instruments Could Hit New Highs Soon
- How to Invest in the FAANG Stocks
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
